Yu Jihui, CFO of Sundia Meditech Company, a Chinese subcontractor performing R&D outsourced by big pharma and biotech companies, tells CT how it limits its euro exposure, the benefits of banking with China’s non-state-owned lenders and why it’s delaying its IPO.
Jun 11, 2012
Sign up for CorporateTreasurer’s Newsletter
Top news, insights and analysis every Tuesday & Thursday
Free registration gives you access to our email newsletters